회사소개
현재 개발 중인 면역항암제는
면역 조절성 ‘mOTS-400’ 항암 바이러스 시리즈와
이를 기반으로 하는 ‘UTTA CAR-T’ 세포치료제로써,
고형암 표적 첨단바이오의약품 개발에 주력하고 있습니다.
바이오녹스 미션
중개 연구 기반 지식과 노하우들이 축적된
면역항암치료제의 개발 지향합니다.
Develop cancer immunotherapies based on constant translational research
바이오녹스 핵심가치
자기 개발을 통한 회사의 발전
Ensure personal and
product integrity
서로 존중하는 커뮤니케이션 및 협업
Communicate and
collaborate with respect
최고 수준의 기술개발을 통한 글로벌 리더쉽의 창출
Promote personal and
organizational improvement
LEADERSHIP
CEO
Soobeom Yi
Economics, Seoul National University
MBA, Stanford University
(former) SEVP, Wonik Investment Partners Co. Ltd.
(former) CEO, F&V Partners Inc.
(former) CEO, Nemo Partners Inc.
CTO
Tae-Ho Hwang
PhD
School of Dentistry, Pusan National University (PNU)
Director & Professor of Medical Research Center (MRC), Pusan National University School of Medicine.
Director of Clinical Trial Center, Pusan National University Yangsan Hospital
15-years global experience in oncolytic virus development
Major authorship of multiple publication in Lancet Oncology, Nature Medicine, Science Translation
Medicine etc.
CMO
Mong Cho
PhD/M.D
Medical School, PNU
Professor of Medical School, PNU
Board of Director, Korean Association for the Study of the Liver
Director of Treatment, Pusan National University Yangsan Hospital
Experience in leading clinical studies on oncolytic virus
Principle Investigator of multiple clinical studies on cancer immunotherapeutics